BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35967294)

  • 21. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
    Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G
    Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
    Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
    Front Immunol; 2019; 10():390. PubMed ID: 30899264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.
    Zhang T; Song X; Xu L; Ma J; Zhang Y; Gong W; Zhang Y; Zhou X; Wang Z; Wang Y; Shi Y; Bai H; Liu N; Yang X; Cui X; Cao Y; Liu Q; Song J; Li Y; Tang Z; Guo M; Wang L; Li K
    Cancer Immunol Immunother; 2018 Jul; 67(7):1079-1090. PubMed ID: 29687231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.
    Mehta N; Maddineni S; Kelly RL; Lee RB; Hunter SA; Silberstein JL; Parra Sperberg RA; Miller CL; Rabe A; Labanieh L; Cochran JR
    Sci Rep; 2020 Sep; 10(1):15171. PubMed ID: 32938950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
    Parren PW; Warmerdam PA; Boeije LC; Capel PJ; van de Winkel JG; Aarden LA
    J Immunol; 1992 Feb; 148(3):695-701. PubMed ID: 1530954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a fab-Peptide sequence.
    Lundström SL; Fernandes-Cerqueira C; Ytterberg AJ; Ossipova E; Hensvold AH; Jakobsson PJ; Malmström V; Catrina AI; Klareskog L; Lundberg K; Zubarev RA
    PLoS One; 2014; 9(11):e113924. PubMed ID: 25426976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
    Deveuve Q; Lajoie L; Barrault B; Thibault G
    Front Immunol; 2020; 11():168. PubMed ID: 32117299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.
    Noelle RJ; Lines JL; Lewis LD; Martell RE; Guillaudeux T; Lee SW; Mahoney KM; Vesely MD; Boyd-Kirkup J; Nambiar DK; Scott AM
    Front Oncol; 2023; 13():1225081. PubMed ID: 37795437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
    Chen X; Song X; Li K; Zhang T
    Front Immunol; 2019; 10():292. PubMed ID: 30863404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
    Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.
    Notter M; Ludwig WD; Bremer S; Thiel E
    Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monomeric IgG2 enhances Ig production and proliferation in human B cells.
    Kimata H; Yoshida A; Ishioka C; Jiang Y; Kusunoki T; Mikawa H
    Biotechnol Ther; 1993; 4(1-2):1-16. PubMed ID: 8374507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VISTA: Coming of age as a multi-lineage immune checkpoint.
    ElTanbouly MA; Schaafsma E; Noelle RJ; Lines JL
    Clin Exp Immunol; 2020 May; 200(2):120-130. PubMed ID: 31930484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T cell activation by anti-T3 antibodies: comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors.
    Smith KG; Austyn JM; Hariri G; Beverley PC; Morris PJ
    Eur J Immunol; 1986 May; 16(5):478-86. PubMed ID: 2938973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen).
    Lanier LL; Kipps TJ; Phillips JH
    J Exp Med; 1985 Dec; 162(6):2089-106. PubMed ID: 2415663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc gamma receptors for murine IgG2a and inability to cross-link the T3-Ti complex.
    Ceuppens JL; Bloemmen FJ; Van Wauwe JP
    J Immunol; 1985 Dec; 135(6):3882-6. PubMed ID: 2933454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
    Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
    Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.